Alzheimer Disease

Zinc-binding agonists affect recognition of beta-amyloid epitopes

Published in Vaccine Weekly, October 20th, 2004

Zinc binding agonists affect the recognition of the beta-amyloid (4-10) epitope by anti-beta-amyloid antibodies.

"Amyloid plaques associated to Alzheimer disease present a high content of zinc ions. We previously showed that the N-terminal region of the amyloid peptide A-beta constitutes an autonomous zinc-binding domain. This region encompasses the previously identified epitope A-beta(4-10) targeted by antibodies capable to reduce amyloid deposition, but the influence of A-beta/Zn binding on the epitope recognition remains unknown," investigators in France report.

"We demonstrate here the effect of Zn²⁺ ions on the recognition of peptides...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry